Asthma and COPD Inhalers containing Ozone-depleting CFCs to be Phased Out
The US Food and Drug Administration has announced, in accordance with longstanding US obligations under the Montreal Protocol on Substances that Deplete the Ozone Layer, seven metered-dose inhalers (MDI) used to treat asthma and chronic obstructive pulmonary disease (COPD) will be gradually removed from the US marketplace.
